Name | AZD1390 |
---|---|
Synonyms | MFCD31619275 |
Description | AZD1390 is an ATM inhibitor. |
---|---|
Related Catalog | |
Target |
ATM |
In Vivo | Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390[2]. |
Animal Admin | Mouse GL261 glioma (p53 mutant) cells are implanted intra-cranially into immunocompetent, syngeneic C57/bl6 mice followed by bioluminescent imaging (BLI) prior to randomization. AZD1390 is administered by oral gavage prior to deliver multiple fractions of 2-3 Gy of radiation on 2 to 4 consecutive days. Radiation is administered via small animal radiation research platform (SARRP) irradiation to the site of the tumor with a 5×5 mm lateral field[2]. |
References |
Molecular Formula | C27H32FN5O2 |
---|---|
Molecular Weight | 477.57 |
Storage condition | -20℃ |
Hazard Codes | N |
---|